8 results about "NOD2" patented technology

The disclosure provides the development of enantiomer-specific 7V-arylpyrazole dipeptides as novel N0D2 agonists which are effective at promoting immune checkpoint inhibitor therapy requiring N0D2 for activity. Given the significant functions of N0D2 in innate and adaptive immunity, these novel agonists afford new therapeutic compounds for a variety of NOD2-responsive diseases.

The present invention relates to a composition for preventing or treating inflammatory diseases, comprising a Lactobacillus sakei CVL-001 strain. The composition activates NOD2, which is an inflammation regulator, and exhibits the effects of inhibiting weight loss and improving clinical activity scores (disease activity index; DAI) in an animal model in which ulcerative colitis is induced, and thus the present invention can be effectively used in the prevention, treatment or alleviation of inflammatory diseases.

The application discloses an application of NOD2 antagonist 1 in preparation of a medicine for preventing or treating depression, and belongs to the technical field of medicines. Specifically, the application relates to an application of a compound NOD2 antagonist 1 in preparation of a medicine for preventing or treating depression. The CAS registration number of the compound NOD2 antagonist 1 is 2411441-54-6. The application discloses a brand-new medicinal use of NOD2 antagonist 1, that is, the compound can be used for preparing a medicine for preventing or treating depression. Animal experiment results show that after intervention of NOD2 antagonist 1, the sucrose preference behavior of a depression model mouse is obviously improved, and depression-related emotional disorder performance is also obviously relieved. Based on the pharmacodynamic verification results, the technical scheme provided by the application has good clinical transformation and popularization and application prospects.

The present invention relates to a microorganism belonging to the genus Akkermansia, having a 16S rRNA gene comprising a nucleotide sequence etc. having homology of more than 98.0% to a nucleotide sequence set forth in SEQ ID NO: 3, having NOD2 agonistic activity, having assimilability to D-mannitol, being a Gram-negative, anaerobic bacterium with a spherical to short rod-shaped form, being negative in an oxidase test, and being positive in a catalase test, and a microorganism for activating NOD2, activating immunity, etc., comprising the microorganism as an active ingredient.

Bronchial remodelling is a prominent feature of severe asthma and a potential therapeutic target. Some data indicate that Th17 cytokines in particular IL-22 may be involved in remodelling processes in vitro, and in skin remodelling in vivo. The aim of the inventors was to evaluate if Th17 cytokines are involved in bronchial remodelling in a severe model of allergic asthma, and if this was amplified by co-sensitization with NOD2 agonist, MDP, a ligand favouring Th17 polarization. Dog allergen challenge led to a predominant neutrophilic infiltration in Broncho-alveolar lavage (BAL), increased dog-specific IgE production, airways hyperresponsiveness, and increased Th17 cytokine production. Increased bronchial remodeling was observed in dog allergen challenged mice compared to control. IL-22 deficiency decreased airway hyperresponsiveness, bronchial mucus production as well as peribronchial collagen deposition, in the allergen-challenged group. Th17 cytokines in particular IL-22 participate in the bronchial remodeling in a chronic model of neutrophilic asthma, and may represent a therapeutic target in severe asthma.

Methods to promote thymic regeneration are described. The methods can inhibit nucleotide-binding oligomerization domain-containing protein 2 (NOD2), Rho GTPases, and / or microRNA 29c (miR29c). These inhibition methods can promote regenerative molecules, such as interleukin (IL)-22, IL-23, and / or bone morphogenetic protein 4 (BMP4). Promoting thymic regeneration can be beneficial in patients due to age, infection, or cancer therapies.

The present invention relates to a vaccine immune adjuvant that utilizes the synergy between imiquimod and a Nod2 receptor-stimulating component or a Nod2 receptor-stimulating bacterium. According to one aspect of the present invention, a vaccine immune adjuvant composition comprising, as active ingredients, imiquimod and a Nod2 receptor-stimulating component or a Nod2 receptor-stimulating bacterium can enhance the efficacy of a vaccine to be greater than that of the administration of imiquimod alone, and thus can be effectively used as a complex immune adjuvant for increasing immune responses of various vaccines such as an SARS-CoV-2 virus vaccine, an influenza A virus vaccine and an anticancer vaccine against melanoma.

The invention is directed to a monoester compound of Formula (1) which is a desmuramylpeptide (DMP) analogue of muramyl dipeptide (MDP), and also to medical uses of the compound such as treating disorders and diseases (e.g. Crohn's disease) wherein the treatment is affected or facilitated by the compound acting as a potent and selective NOD2 agonist.